Agenus Inc.
AGENAgenus Inc. (AGEN) is a biotechnology company focused on the development of immunotherapies for cancer and infectious diseases. Founded in 1994, the company specializes in the research and development of innovative vaccine adjuvants and immune checkpoint modulators aimed at enhancing the body's immune response. Agenus's portfolio includes a range of monoclonal antibodies, vaccines, and other immunotherapeutic products targeting unmet medical needs.
Company News
A comprehensive market report reveals over 40 companies developing 50+ CTLA-4 inhibitor drugs for cancer immunotherapy. Key developments include FDA approvals for tremelimumab in hepatocellular cancer and MT-8421 for solid tumors, along with promising clinical progress from multiple biopharmaceutical companies in checkpoint inhibitor combinations...
Agenus reported Q3 2024 results highlighting groundbreaking clinical progress with BOT/BAL immunotherapy in hard-to-treat cancers, particularly microsatellite-stable colorectal cancer. However, the company faces significant financial constraints with only $44.8 million in cash at quarter-end. Management is pursuing cost reductions, real estate as...
The FDA is tightening survival standards in cancer research, with private investments helping to fill public funding gaps. Several biotech companies are advancing innovative immunotherapies, with Oncolytics Biotech showing promising results in pancreatic cancer treatment.
PD-(L)1 inhibitors are projected to dominate future drug sales, revolutionizing cancer care across multiple tumor types with flexible treatment approaches and promising clinical outcomes.
The U.S. pharmaceutical Contract Development and Manufacturing Organization (CDMO) market is expected to grow from $36.77 billion in 2024 to $68.57 billion by 2034, driven by increased demand for specialized pharmaceutical services, technological advancements, and growing needs in oncology and complex drug development.
